Photocure ASA: Blue Light Cystoscopy with Hexvix® reduces recurrence rate at 3 years in real-life experience study
(WorldNews Norway)

Photocure ASA: Blue Light Cystoscopy with Hexvix® reduces recurrence rate at 3 years in real-life experience study 18.08.2017 08:57 Oslo, Norway, August 18, 2017: Photocure ASA (OSE: PHO) today announced that a prospective controlled study investigating the introduction of Blue Light Cystoscopy (BLC(TM)) with Hexvix® at first presentation in patients with non-muscle invasive bladder cancer (NMIBC) in routine clinical practice has been published in the World Journal of Urology http://bit.ly/RealLifeBLCC. The overall recurrence rates at 3 years were significantly less in patients who received BLC(TM)with Hexvix® (39.0%) compared to an optimized White Light Cystoscopy (WLC) resection (53.3% ;...